{"id":"https://openalex.org/W4367173391","doi":"https://doi.org/10.1158/2326-6066.c.6620888.v1","title":"Data from Anti\u2013PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression","display_name":"Data from Anti\u2013PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression","publication_year":2023,"publication_date":"2023-04-27","ids":{"openalex":"https://openalex.org/W4367173391","doi":"https://doi.org/10.1158/2326-6066.c.6620888.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6620888.v1","doi":"https://doi.org/10.1158/2326-6066.c.6620888.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6620888.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2326-6066.c.6620888.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032538191","display_name":"Zachariah Peter Tritz","orcid":"https://orcid.org/0000-0002-5836-7839","observed_orcids":["https://orcid.org/0000-0002-5836-7839","https://orcid.org/0000-0003-0124-4376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zachariah P. Tritz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5836-7839","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084993777","display_name":"Katayoun Ayasoufi","orcid":"https://orcid.org/0000-0002-3797-0823","observed_orcids":["https://orcid.org/0000-0002-3797-0823"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katayoun Ayasoufi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3797-0823","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085689112","display_name":"Delaney M. Wolf","orcid":"https://orcid.org/0000-0003-3883-2489","observed_orcids":["https://orcid.org/0000-0003-3883-2489"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Delaney M. Wolf","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3883-2489","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007178953","display_name":"Carley A. Owens","orcid":"https://orcid.org/0000-0003-3614-4076","observed_orcids":["https://orcid.org/0000-0003-3614-4076"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carley A. Owens","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3614-4076","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076599272","display_name":"Courtney Sarah Malo","orcid":"https://orcid.org/0000-0001-9674-3826","observed_orcids":["https://orcid.org/0000-0001-9674-3826"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Courtney S. Malo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9674-3826","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022053658","display_name":"Benjamin T. Himes","orcid":"https://orcid.org/0000-0001-5420-068X","observed_orcids":["https://orcid.org/0000-0001-5420-068X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin T. Himes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5420-068X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024074311","display_name":"Cori E. Fain","orcid":"https://orcid.org/0000-0002-8323-6419","observed_orcids":["https://orcid.org/0000-0002-8323-6419"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cori E. Fain","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8323-6419","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090612293","display_name":"Emma N. Goddery","orcid":"https://orcid.org/0000-0001-6632-8226","observed_orcids":["https://orcid.org/0000-0001-6632-8226"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emma N. Goddery","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6632-8226","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002497763","display_name":"Lila T. Yokanovich","orcid":"https://orcid.org/0000-0002-3823-4051","observed_orcids":["https://orcid.org/0000-0002-3823-4051"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lila T. Yokanovich","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3823-4051","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086264670","display_name":"Fang Jin","orcid":"https://orcid.org/0000-0001-9325-7179","observed_orcids":["https://orcid.org/0000-0001-9325-7179"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fang Jin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9325-7179","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028069544","display_name":"Michael J. Hansen","orcid":"https://orcid.org/0000-0001-7712-0375","observed_orcids":["https://orcid.org/0000-0001-7712-0375"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael J. Hansen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7712-0375","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042333597","display_name":"Ian F. Parney","orcid":"https://orcid.org/0000-0002-9702-8047","observed_orcids":["https://orcid.org/0000-0002-9702-8047"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian F. Parney","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9702-8047","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010999533","display_name":"Chensu Wang","orcid":"https://orcid.org/0000-0001-6996-149X","observed_orcids":["https://orcid.org/0000-0001-6996-149X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chensu Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6996-149X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043334947","display_name":"Kelly Dare Moynihan","orcid":"https://orcid.org/0000-0001-6200-7863","observed_orcids":["https://orcid.org/0000-0001-6200-7863"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelly D. Moynihan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6200-7863","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087926553","display_name":"Darrell J. Irvine","orcid":"https://orcid.org/0000-0002-8637-1405","observed_orcids":["https://orcid.org/0000-0002-8637-1405"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darrell J. Irvine","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8637-1405","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111326412","display_name":"Karl Dane Wittrup","orcid":"https://orcid.org/0000-0003-2398-5896","observed_orcids":["https://orcid.org/0000-0003-2398-5896"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Dane Wittrup","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2398-5896","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002347861","display_name":"Rosa M. Diaz Marcano","orcid":"https://orcid.org/0000-0002-1545-5679","observed_orcids":["https://orcid.org/0000-0002-1545-5679"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rosa M. Diaz Marcano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1545-5679","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070554485","display_name":"Richard G. Vile","orcid":"https://orcid.org/0000-0003-2192-9372","observed_orcids":["https://orcid.org/0000-0003-2192-9372"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard G. Vile","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2192-9372","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5044624530","display_name":"Aaron J. Johnson","orcid":"https://orcid.org/0000-0002-7921-484X","observed_orcids":["https://orcid.org/0000-0002-7921-484X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aaron J. Johnson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7921-484X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.04580000042915344,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.8669999837875366},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9750000238418579},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.9089999794960022},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.9800000190734863},{"id":"https://openalex.org/keywords/antigen-presentation","display_name":"antigen presentation","score":0.7459999918937683},{"id":"https://openalex.org/keywords/gl261-glioma","display_name":"GL261 glioma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/tumor-rechallenge","display_name":"tumor rechallenge","score":0.5540000200271606},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.6150000095367432},{"id":"https://openalex.org/keywords/murine-glioma-model","display_name":"murine glioma model","score":0.6389999985694885}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7033874988555908},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.672714352607727},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.6270490884780884},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.58104008436203},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5577081441879272},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5138009190559387},{"id":"https://openalex.org/C170627219","wikidata":"https://www.wikidata.org/wiki/Q13218497","display_name":"MHC class I","level":4,"score":0.5135939121246338},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4651291072368622},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.44170334935188293},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4406389594078064},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41546663641929626},{"id":"https://openalex.org/C2778814158","wikidata":"https://www.wikidata.org/wiki/Q959350","display_name":"MHC class II","level":4,"score":0.415388822555542},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4070546329021454},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3771664798259735},{"id":"https://openalex.org/C207936829","wikidata":"https://www.wikidata.org/wiki/Q423163","display_name":"Major histocompatibility complex","level":3,"score":0.34908318519592285},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.24531537294387817},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15720227360725403},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6620888.v1","doi":"https://doi.org/10.1158/2326-6066.c.6620888.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6620888.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6620888.v1","doi":"https://doi.org/10.1158/2326-6066.c.6620888.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6620888.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4324323843","https://openalex.org/W3217183611","https://openalex.org/W4313383138","https://openalex.org/W4319433783","https://openalex.org/W4313430114","https://openalex.org/W4388588698","https://openalex.org/W2605513047","https://openalex.org/W2969843369","https://openalex.org/W4392722637","https://openalex.org/W4416139738"],"abstract_inverted_index":{"Abstract":[0],"Glioblastoma":[1],"(GBM)":[2],"is":[3,185,225],"the":[4,120,124,228,249],"most":[5,22],"common":[6],"malignant":[7,53],"brain":[8],"tumor":[9,139],"in":[10,68,137,141,151],"adults,":[11],"responsible":[12],"for":[13,52,246],"approximately":[14,106],"225,000":[15],"deaths":[16],"per":[17],"year.":[18],"Despite":[19],"preclinical":[20],"successes,":[21],"interventions":[23],"have":[24],"failed":[25],"to":[26,64,73,96,131,147,192,205],"extend":[27],"patient":[28],"survival":[29,118,157],"by":[30],"more":[31],"than":[32],"a":[33,84,135,155],"few":[34],"months.":[35],"Treatment":[36],"with":[37,79,187],"anti\u2014programmed":[38],"cell":[39],"death":[40],"protein":[41],"1":[42],"(anti\u2013PD-1)":[43],"immune":[44],"checkpoint":[45,99],"blockade":[46,100],"(ICB)":[47],"monotherapy":[48],"has":[49,62],"been":[50],"beneficial":[51],"tumors":[54,247],"such":[55],"as":[56,97,128],"melanoma":[57],"and":[58,115,172,179,238],"lung":[59],"cancers":[60],"but":[61,215],"yet":[63],"be":[65,206],"effectively":[66],"employed":[67],"GBM.":[69],"This":[70,91,183],"study":[71],"aimed":[72],"determine":[74],"whether":[75],"supplementing":[76],"anti\u2013PD-1":[77],"ICB":[78,244],"engineered":[80],"extended":[81],"half-life":[82],"IL2,":[83],"potent":[85],"lymphoproliferative":[86],"cytokine,":[87],"could":[88],"improve":[89],"outcomes.":[90],"combination":[92],"therapy,":[93],"subsequently":[94],"referred":[95],"enhanced":[98],"(ECB),":[101],"delivered":[102],"intraperitoneally,":[103],"reliably":[104],"cures":[105],"50%":[107],"of":[108,119,143,165,176,198,208,248],"C57BL/6":[109],"mice":[110],"bearing":[111],"orthotopic":[112],"GL261":[113,194,229],"gliomas":[114],"extends":[116],"median":[117],"treated":[121],"cohort.":[122],"In":[123],"CT2A":[125,138],"model,":[126],"characterized":[127],"being":[129],"resistant":[130],"CBI,":[132],"ECB":[133,159,189,224],"caused":[134],"decrease":[136],"volume":[140],"half":[142],"measured":[144],"animals":[145],"similar":[146],"what":[148],"was":[149,203],"observed":[150],"GL261-bearing":[152],"mice,":[153],"promoting":[154],"trending":[156],"increase.":[158],"generates":[160],"robust":[161],"immunologic":[162],"responses,":[163],"features":[164],"which":[166],"include":[167],"secondary":[168],"lymphoid":[169],"organ":[170],"enlargement":[171],"increased":[173],"activation":[174],"status":[175],"both":[177],"CD4":[178,218],"CD8":[180],"T":[181,219],"cells.":[182,220],"immunity":[184],"durable,":[186],"long-term":[188],"survivors":[190],"able":[191],"resist":[193],"rechallenge.":[195],"Through":[196],"employment":[197],"depletion":[199],"strategies,":[200],"ECB's":[201],"efficacy":[202],"shown":[204],"independent":[207],"host":[209],"MHC":[210,234],"class":[211,235],"I\u2013restricted":[212],"antigen":[213],"presentation":[214],"reliant":[216],"on":[217],"These":[221],"results":[222],"demonstrate":[223],"efficacious":[226],"against":[227],"glioma":[230],"model":[231],"through":[232],"an":[233],"I\u2013independent":[236],"mechanism":[237],"supporting":[239],"further":[240],"investigation":[241],"into":[242],"IL2-supplemented":[243],"therapies":[245],"central":[250],"nervous":[251],"system.":[252]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-04-28T00:00:00"}